Approaches to Mitigate Blindness Associated with Neovascular Age-Related Macular Degeneration

https://www.pharmacytimes.org/on-demand/a-managed-care-review-approaches-to-mitigate-blindness-associated-with-neovascular-agerelated-macular-degeneration

Related Videos

Related Content

Advertisement

December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein

The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.

December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.

December 20th 2024

FDA Approves Encorafenib With Cetuximab and mFOLFOX6 for Metastatic CRC

Julia Bonavitacola

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

Brooke McCormick

In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.

December 20th 2024

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

Cameron Santoro

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

Related Content

Advertisement

December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein

The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.

December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.

December 20th 2024

FDA Approves Encorafenib With Cetuximab and mFOLFOX6 for Metastatic CRC

Julia Bonavitacola

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

Brooke McCormick

In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.

December 20th 2024

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

Cameron Santoro

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.